Effects of HIV protease inhibitor ritonavir on vasomotor function and endothelial nitric oxide synthase expression

Journal of Acquired Immune Deficiency Syndromes

Volumn 39, Issue 2, 2005, Pages 152-158

  Fu, Weiping ^a   Chai, Hong ^a   Yao, Qizhi ^a   Chen, Changyi ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Coronary artery; Endothelial cell; HIV protease inhibitor; Nitric oxide synthase; Porcine; Ritonavir

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; BRADYKININ; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MESSENGER RNA; NITROPRUSSIDE SODIUM; PROTEINASE INHIBITOR; RITONAVIR;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MUSCLE CONTRACTION; MUSCLE RELAXATION; MUSCLE TONE; MYOGRAPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASOMOTOR REFLEX;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ANIMALS; BASE SEQUENCE; BRADYKININ; CORONARY VESSELS; DNA PRIMERS; ENDOTHELIUM, VASCULAR; HIV PROTEASE INHIBITORS; HUMANS; MOTOR ACTIVITY; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; NITROPRUSSIDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RITONAVIR; SWINE;

EID: 19644397572     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Barbara G. Highly active antiretroviral therapy and the cardiovascular system: the heart of the matter. Pharmacology, 2003;69:177-179.
2. Leen CL. Perspectives on HAART: switch maintenance therapy. Int J STD AIDS. 2003;14:577-582.
3. Barbaro G. HIV infection, antiretroviral therapy and cardiovascular risk. J Cardiovasc Risk. 2002;9:295-300.
4. Rhew DC, Bernal M, Aguilar D, et al. Association between protease inhibitor use and increased cardiovascular risk in patients infected with human immunodeficiency virus: a systematic review. Clin Infect Dis. 2003;37:959-972.
5. Calza L, Manfredi R, Chiodo F. Hyperlipidaemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management. Int J Antimicrob Agents. 2003;22:89-99.
6. Pumell JQ, Zambon A, Knopp RH, et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS. 2000;14:51-57.
7. Zhong DS, Lu XH, Conklin BS, et al. HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells. Arterioscler Thromb Vasc Biol. 2002;22:1560-1566.
8. Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation. 2001;104:257-262.
9. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373-376.
10. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993;329:2002-2012.
11. Ignarro LJ. Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein. Circ Res. 1989; 65:1-21.
12. Arnal JF, Dinh-Xuan AT, Pueyo M, et al. Endothelium-derived nitric oxide and vascular physiology and pathology. Cell Mol Life Sci. 1999;55:1078-1087.
13. Shaul PW. Endothelial nitric oxide synthase, caveolae and the development of atherosclerosis. J Physiol. 2003;547:21-33.
14. Surowiec SM, Conklin BS, Li JS, et al. A new perfusion culture system used to study human vein. J Surg Res. 2000;88:34-41.
15. Spencer TA, Chai H, Fu W, et al. Estrogen blocks homocysteine-induced endothelial dysfunction in porcine coronary arteries. J Surg Res. 2004; 118:83-90.
16. Barbaro G, Di Lorenzo G, Cirelli A, et al. An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV infection receiving highly active antiretroviral therapy. Clin Ther. 2003;25:2405-2418.
17. Barbaro G. Protease inhibitors and mortality among children and adolescents infected with H1V-1. N Engl J Med. 2002;346:1026-1027.
18. Fantoni M, Autore C, Del Borgo C. Drugs and cardiotoxicity in HIV and AIDS. Ann NY Acad Sci. 2001;946:179-199.
19. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors, Lancet. 1998;351:1328.
20. Conklin BS, Fu W, Lin PH, et al. HIV protease inhibitor ritonavir decreases endothelium-dependent vasorelaxation and increases superoxide in porcine arteries. Cardiavasc Res. 2004;63:168-175.
21. Nedeljkovic ZS, Gokce N, Loscalzo J, Mechanisms of oxidative stress and vascular dysfunction. Postgrad Med J. 2003;79:195-199.
22. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000;87:840-844.
23. Wilcox JN, Subramanian RR. Sundell CL, et al. Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels. Arterioscler Thromb Vasc Biol. 1997;17:2479-2488.
24. Berka V, Tsai AL. Characterization of interactions among the heme center, tetrahydrobiopterin, and L-arginine binding sites of ferric eNOS using imidazole, cyanide, and nitric oxide as probes. Biochemistry. 2000;39: 9373-9383.
25. Pou S, Pou W, Bredt D, et al. Generation of superoxide by purified brain nitric oxide synthase. J Biol Chem. 1992;267:24173-24176.
26. Shimokawa H, Flavahan NA, Vanhoutte PM. Loss of endothelial pertussis toxin-sensitive G protein function in atherosclerotic porcine coronary arteries. Circulation. 1991;83:652-660.
27. Harrison DG. Endothelial function and oxidant stress. Clin Cardiol. 1997;20:II11-II17.
28. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: part II: animal and human studies, Circulation. 2003;108:2034-2040.
29. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: part I: basic mechanisms and in vivo monitoring of ROS. Circulation. 2003;108:1912-1916.
30. Huang MB, Khan M, Garcia-Barrio M, et al. Apoptotic effects in primary human umbilical vein endothelial cell cultures caused by exposure to virion-associated and cell membrane-associated HIV-1 gp120. J Acquir Immune Defic Syndr. 2001;27:213-221.
31. Fiala M, Murphy T, MacDougall J, et al. HAART drugs induce mitochondrial damage and intercellular gaps and gp120 causes apoptosis. Cardiovasc Toxicol. 2004;4:327-338.
32. Fleischer R, Boxwell D, Sherman KE. Nucleoside analogues and mitochondrial toxicity. Clin Infect Dis. 2004;38:e79-e80.